

Drug Monograph

Drug Name: **Lyumjev™ (insulin lispro-aabc) KwikPen and Vial**
 Drug Class: **Insulins, Rapid-Acting**
 Prepared For: MO HealthNet
 Prepared By: Conduent

New Criteria

Revision of Existing Criteria

Executive Summary

Purpose: The purpose of this monograph is to provide a review of new therapy to determine whether the reviewed drug should be made available on an open access basis to prescribers, require a clinical edit or require prior authorization for use.

Dosage Forms: Lyumjev is available as insulin lispro-aabc 100 units/mL injection in a 10 mL multiple-dose vial and single-patient use 3 mL KwikPen. Lyumjev is also available as insulin lispro-aabc 200 units/mL injection single-patient use 3 mL KwikPen.

Manufacturer: Eli Lilly and Company, Indianapolis, IN 46285.

Indications: Lyumjev is indicated to improve glycemic control in adults with diabetes mellitus

Costs: 100 u/mL: \$274/10 mL vial; \$530.40/box of 5 pens Wholesale Acquisition Cost
 200 u/mL: \$1,060.80/box of 5 pens Wholesale Acquisition Cost

Summary of Findings: This drug is being considered for inclusion in the state specific Preferred Drug List (PDL) as non-preferred.

Status Recommendation: Clinical Edit PA Required
 Open Access PDL

Type of PA Criteria: Appropriate Indications Non-Preferred
 No PA Required Preferred

Prepared by: Megan Fast, PharmD
 Date: August 5, 2020